Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antibacterial Agents Clear all
Recruiting No phase listed Observational

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
Jelmyto (mitomycin) for pyelocalyceal solution
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02961764
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Usual Care, Dalbavancin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use

NCT03489330
View directory record Official record
Conditions
Infectious Disease
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission

NCT00021671
View directory record Official record
Conditions
HIV Infections
Interventions
Erythromycin, Nevirapine, Ampicillin sodium, Metronidazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
3,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)

NCT02227446
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Vancomycin antibiotic powder
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031
View directory record Official record
Conditions
Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TOBI® PODHALER®, TOBI®, Bethkis®, Cayston®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Bellflower, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Not applicable Interventional Results available

Antibiotic Prophylaxis for Simple Hand Lacerations

NCT01155154
View directory record Official record
Conditions
Simple Hand Lacerations
Interventions
cephalexin, clindamycin, placebo
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Brooklyn, New York • Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections

NCT06702878
View directory record Official record
Conditions
Surgical Site Infections, Surgical Wound Infection, Infections, Anti-Infective Agents
Interventions
nasal antimicrobial photodisinfection therapy
Combination Product
Lead sponsor
Ondine Biomedical Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Englewood, Colorado • Brandon, Florida • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

NCT06110494
View directory record Official record
Conditions
Apical Periodontitis, Pulp Disease, Dental
Interventions
Iron oxide nanoparticles treatment Ferumoxytol/H2O2, NaOCl, NaCl, supplementary irrigation
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Antimicrobial Drug Use and Resistant Staphylococcus Aureus

NCT01075451
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 22, 2026, 3:59 PM EDT
Completed No phase listed Observational

Antimicrobial PK in Infants With Suspected or Confirmed Infection

NCT00491426
View directory record Official record
Conditions
Infection
Interventions
Ampicillin, Metronidazole, Piperacillin/Tazobactam, Acyclovir, Amphotericin B, Ambisome, Anidulafungin, Caspofungin
Drug
Lead sponsor
Duke University
Other
Eligibility
Up to 120 Days
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional Results available

Daily Checklists and Outcome in the Intensive Care Unit

NCT01396044
View directory record Official record
Conditions
Critical Illness
Interventions
Electronic checklist, Verbal prompting
Other
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Jul 22, 2026, 3:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

NCT05846399
View directory record Official record
Conditions
Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
Interventions
Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
Drug · Other · Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 3:59 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 22, 2026, 3:59 PM EDT
Not yet recruiting Phase 4 Interventional

Non-antibiotic Management in Acute Uncomplicated Diverticulitis

NCT07625267
View directory record Official record
Conditions
Acute Uncomplicated Diverticulitis
Interventions
Symptomatic treatment (ibuprofen and acetaminophen), Amoxicillin-clavulanate, Ciprofloxacin plus metronidazole
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery

NCT01296542
View directory record Official record
Conditions
Cataracts
Interventions
Moxifloxacin Ophthalmic, Besifloxacin Ophthalmic
Drug
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA

NCT04597008
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Treatment group, Control group
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Redwood City, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jul 22, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

"Clinical Trials to Enhance Elders' Oral Health" ("TEETH")

NCT00004640
View directory record Official record
Conditions
Tooth Loss, Periodontal Disease, Tooth Decay
Interventions
Chlorhexidine rinse
Drug
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 75 Years
Enrollment
1,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Jul 22, 2026, 3:59 PM EDT
Withdrawn Phase 2 Interventional

Preventing Frequent Sinus Infections in HIV-Infected Patients

NCT00000752
View directory record Official record
Conditions
HIV Infections, Sinusitis
Interventions
Pseudoephedrine hydrochloride, Guaifenesin, Cefuroxime axetil, Beclomethasone dipropionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 22, 2026, 3:59 PM EDT